ME/CFS AUSTRALIA (SA) INC
Registered Charity 698
PO Box 28,
South Australia 5007
North Terrace House,
19 North Terrace,
Hackney, SA, 5069
1300 128 339
ME/CFS Australia (SA) Inc supports the needs of sufferers of Myalgic Encephalomyelitis, Chronic Fatigue Syndrome and related illnesses. We do this by providing services and information to members.
ME/CFS Australia (SA) Inc aims to keep members informed of various research projects, diets, medications, therapies, news items, etc. All communication, both verbal and written, is merely to disseminate information and not to make recommendations or directives.
Unless otherwise stated, the views expressed on this Web site are not necessarily the official views of the Society or its Committee and are not simply an endorsement of products or services.
Severe Fatigue May Be Prevalent Among Patients With Inflammatory Rheumatic Diseases
Saturday 27 February 2016
Severe fatigue may be prevalent among patients with inflammatory rheumatic diseases
Patients with inflammatory rheumatic diseases were more likely than patients with osteoarthritis to experience severe fatigue, which was prevalent among patients, according to allied researchers from Europe and the United States.
Researchers studied 6,120 patients with rheumatic diseases enrolled in an online study of patient perceptions about invalidation between November 2009 and September 2011. Perceptions included beliefs that others deny, lecture, do not acknowledge or are unsupportive of the patients’ disease.
Rheumatic diseases included fibromyalgia (n = 2,993; 49%), osteoarthritis (n = 1,249; 20%), rheumatoid arthritis (n = 1,054; 17%), systemic lupus erythematosus (n = 804; 13%), ankylosing spondylitis/Bechterew’s disease (n = 621; 10%), Sjögren’s syndrome (n = 567; 9%), psoriatic arthritis (n = 240; 4%), scleroderma (n = 147; 2%), polymyalgia rheumatica (n = 93; 2%), Ehlers-Danlos syndrome or hypermobility syndrome (n = 85; 1%), juvenile idiopathic arthritis (n = 81, 1%), gout or pseudogout (n = 62; 1%), mixed connective tissue disease (n = 56; 1%), Tietze’s syndrome/costochondritis (n = 54; 1%) and another rheumatic disease (n = 149; 2%).
Participants were asked to identify their disease(s) and disease duration and share demographic characteristics.
Fatigue was measured using the Vitality scale of the RAND SF-36. Confounding variables included age, gender, years of education, marital status, language and presence of comorbidities, including fibromyalgia, reported by nearly half of participants.
The most common combinations of rheumatic diseases were fibromyalgia and osteoarthritis (OA); fibromyalgia, OA and another rheumatic disease; OA and another rheumatic disease other than fibromyalgia, including 102 with rheumatoid arthritis (RA); RA and another rheumatic disease other than OA or fibromyalgia.
Severe fatigue was identified in 65% of all patients and in about 80% of all patients with fibromyalgia. Patients with a single inflammatory disease had severe fatigue in 41% to 57% of the patient group, while 35% of patients with osteoarthritis reported severe fatigue.
The presence of fibromyalgia, multiple rheumatic diseases without fibromyalgia and non-Dutch language was associated with an increased likelihood of severe fatigue. Older age, longer disease duration and more years of education decreased the risk for fatigue. Patients with fibromyalgia were four times as likely to have severe fatigue than patients without fibromyalgia, and French-speaking participants were six times as likely to have severe fatigue compared with Dutch-speaking participants. About 64% of Dutch-speaking patients had severe fatigue compared with 85% to 91% of patients with fibromyalgia who spoke another language. – by Shirley Pulawski
Disclosure: The researchers report no relevant financial disclosures.
The full article can be found here.
blog comments powered by Disqus